Hancock Whitney Corp purchased a new stake in shares of Repligen Co. (NASDAQ:RGEN) during the 4th quarter, Holdings Channel.com reports. The fund purchased 24,871 shares of the biotechnology company’s stock, valued at approximately $2,301,000.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Repligen during the first quarter valued at approximately $2,925,000. BlackRock Inc. grew its stake in shares of Repligen by 12.4% during the second quarter. BlackRock Inc. now owns 6,350,552 shares of the biotechnology company’s stock valued at $545,830,000 after purchasing an additional 699,886 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Repligen during the third quarter valued at approximately $1,291,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Repligen during the third quarter valued at approximately $323,000. Finally, Meeder Asset Management Inc. grew its stake in shares of Repligen by 33.0% during the third quarter. Meeder Asset Management Inc. now owns 6,056 shares of the biotechnology company’s stock valued at $464,000 after purchasing an additional 1,504 shares during the last quarter. 84.82% of the stock is currently owned by institutional investors and hedge funds.
RGEN has been the topic of several research analyst reports. Stifel Nicolaus initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “buy” rating and a $105.00 price target on the stock. BidaskClub raised shares of Repligen from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 8th. HC Wainwright reissued a “buy” rating and set a $110.00 price target on shares of Repligen in a research note on Monday, January 13th. Finally, First Analysis raised shares of Repligen from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $107.00 to $110.00 in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $105.63.
Repligen Company Profile
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
Read More: How is the LIBOR rate calculated?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.